Table 1.
Cohort characteristics
| 5-year survivors (n=200 945) | Subsequent primary neoplasms (n=12 321) | |
|---|---|---|
| Sex | ||
| Male | 76 666 (38%) | 4282 (35%) |
| Female | 124 279 (62%) | 8039 (65%) |
| Age at diagnosis of AYA cancer (years) | ||
| 15–19 | 12 248 (6%) | 622 (5%) |
| 20–24 | 21 258 (11%) | 991 (8%) |
| 25–29 | 35 894 (18%) | 1768 (14%) |
| 30–34 | 54 541 (27%) | 3333 (27%) |
| 35–39 | 77 004 (38%) | 5607 (46%) |
| Decade of diagnosis of AYA cancer | ||
| 1971–79 | 25 158 (13%) | 4222 (34%) |
| 1980–89 | 51 573 (26%) | 5017 (41%) |
| 1990–2006 | 124 214 (62%) | 3082 (25%) |
| AYA cancer | ||
| Breast | 36 236 (18%) | 1877 (15%) |
| Testicular | 24 309 (12%) | 1435 (12%) |
| Cervix | 23 281 (12%) | 1675 (14%) |
| Melanoma | 22 446 (11%) | 981 (8%) |
| Hodgkin lymphoma | 16 971 (8%) | 1606 (13%) |
| Non-Hodgkin lymphoma | 9467 (5%) | 511 (4%) |
| Thyroid | 7809 (4%) | 473 (4%) |
| CNS (intracranial)* | 14 616 (7%) | 739 (6%) |
| Colorectal | 5805 (3%) | 537 (4%) |
| Soft-tissue sarcoma | 6130 (3%) | 400 (3%) |
| Ovary | 4885 (2%) | 349 (3%) |
| Leukaemia | 5073 (3%) | 234 (2%) |
| Bladder | 4685 (2%) | 344 (3%) |
| Head and neck | 3961 (2%) | 253 (2%) |
| Lung | 1219 (<1%) | 80 (<1%) |
| Female genital (other)† | 2270 (1%) | 269 (2%) |
| Spinal cord and other CNS | 2602 (1%) | 191 (2%) |
| Other digestive | 1419 (<1%) | 107 (<1%) |
| Urinary (other)‡ | 1979 (1%) | 139 (1%) |
| Bone tumour | 2241 (1%) | 100 (<1%) |
| Male genital (other)§ | 423 (<1%) | 21 (<1%) |
| Other | 3118 (2%) | ..¶ |
| Time since diagnosis of AYA cancer (years) | ||
| 5–9 | 46 679 (23%) | 1863 (15%) |
| 10–19 | 75 801 (38%) | 4381 (36%) |
| 20–29 | 50 793 (25%) | 4285 (35%) |
| ≥30 | 27 672 (14%) | 1792 (15%) |
Data are n (%). AYA=adolescent and young adult.
*
CNS intracranial including brain, meninges, and pituitary gland.
†
Female genital excluding cervix and ovary.
‡
Urinary excluding bladder.
§
Male genital excluding testis.
¶
Other AYA cancers were not included in the analysis of subsequent primary neoplasms.